Examine reveals earlier Omicron an infection most protecting towards BA.2
A examine in The Lancet Infectious Illnesses demonstrates that earlier Omicron BA.1 an infection was probably the most protecting issue towards BA.2 an infection (related to a danger discount of 72%) and gave higher safety than main an infection with pre-Omicron SARS-CoV-2 (38%) or three doses of an mRNA vaccine in individuals with no earlier an infection (46%).
The test-negative case-control examine concerned Quebec healthcare staff to match those that had a optimistic SARS-CoV-2 check in the course of the interval of Omicron BA.2 dominance, from Mar 27 to Jun 4, 2022, with healthcare staff who had a detrimental check throughout the identical interval.
The first COVID-19 an infection needed to happen at the very least 30 days earlier than the examine interval, with pre-Omicron infections occurring between Feb 20, 2020, and Nov 27, 2021. Omicron BA.1 attribution was given for all circumstances between Dec 26, 2021, and Mar 26, 2022. In whole, 37,732 presumed Omicron BA.2 circumstances have been in contrast with 73,507 randomly chosen controls.
The authors mentioned that amongst circumstances, 1,159 (3.1%) had a main an infection mixed with two mRNA vaccine doses, and 1,436 (3.8%) had a main an infection and three vaccine doses. Amongst controls, 687 (10.9%) had a main an infection mixed with two vaccine doses, and 821 (13.4%) had a main an infection and three vaccine doses.
Hybrid immunity from BA.1 an infection plus two or three mRNA vaccine doses elevated effectiveness to 96% for longer than 5 months. Notably, a 3rd vaccine dose conferred no enchancment to that hybrid safety.
“These information present immunological context for the significance of hybrid immunity in managing the present surges attributable to the BA.2.12.1, BA.4, and BA.5 subvariants in populations with excessive frequencies of vaccination and BA.1 or BA.2 an infection,” writes David Hui, MD, of the Chinese language College of Hong Kong, in a commentary on the examine. “One other vital think about lowering an infection danger is heterologous booster vaccination with totally different platforms to maximise the breadth of vaccine-induced immunity, particularly in international locations primarily utilizing inactivated vaccine.”
Sep 21 Lancet Infect Dis study and commentary
Settlement paves manner for higher world Paxlovid entry
Pfizer right this moment introduced that it has signed an settlement with the World Fund to provide as much as 6 million Paxlovid programs for 132 low- and middle-income international locations to assist deal with COVID-19.
The international locations will be capable to entry the drug by way of the World Fund’s current pandemic response mechanism, which has been used to offer grant help for exams, remedies, private protecting gear, and different components for strengthening heathcare programs.
In a press release, Pfizer mentioned it expects the availability to start this 12 months, based mostly on regulatory approval and nation demand. Nations can purchase provides by way of tiered pricing at Pfizer’s nonprofit charge. Albert Bourla, Pfizer’s chief govt officer, mentioned the contact with the World Fund boosts equitable entry to remedies for high-risk teams in low- and middle-income international locations. The corporate additionally mentioned the settlement builds on earlier efforts to ease entry.
In US developments, an official with the Meals and Drug Administration mentioned this week that up to date COVID boosters for kids ages 5 to 11 years outdated will probably be licensed within the coming weeks, in keeping with ABC Information. Peter Marks, MD, PhD, who directs the FDA’s Heart for Biologics Analysis and Analysis, was talking at an occasion with the COVID-19 Vaccine Training and Fairness Challenge. Earlier this month, the brand new booster was cleared for emergency use in individuals as younger as 12.
Sep 22 Pfizer statement
Sep 21 ABC Information story